Publicaciones en colaboración con investigadores/as de Fox Chase Cancer Center (14)

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

  2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  3. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2020

  1. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2018

  1. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 151, Núm. 1, pp. 46-52

2016

  1. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research

2015

  1. A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Núm. 8, pp. 1202-1222

2014

  1. Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning

    Blood, Vol. 124, Núm. 19, pp. 2937-2947

2001

  1. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis

    Human Molecular Genetics, Vol. 10, Núm. 26, pp. 3001-3007

1988

  1. Intraoperative trials

    International Journal of Radiation Oncology, Biology, Physics, Vol. 14, Núm. SUPPL. 1